Abstract
A phase I trial reported positive results for an antibody–drug conjugate that targets HER2-positive tumors. Trastuzumab duocarmazine, which kills tumor cells by causing DNA damage, induced partial responses in 33% of patients whose tumors were resistant to the approved antibody–drug conjugate trastuzumab emtansine. The drug caused fatigue, neutropenia, pneumonitis, and eye-related side effects.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Published OnlineFirst August 2, 2019
doi: 10.1158/2159-8290.CD-NB2019-089
New ADC Shrinks HER2-Positive Tumors
Jump to section
Advertisement